Highest-materiality recent filing
Labcorp management to speak at Morgan Stanley healthcare conference Sept. 15
Executive team will participate in a fireside chat at Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 15, 2026 at 11:30 a.m. ET.
Labcorp to host Investor Day on Sept 10, 2026; CEO and CFO to discuss strategy and outlook
Investor Day scheduled for Thursday, September 10, 2026, 9 a.m. to noon ET.
Labcorp EVP Bailey resigns; Caveney to lead Biopharma Lab Services
Megan D. Bailey resigns as EVP & President, Central Laboratories and International, effective Sept 4, 2026.
Labcorp Q2 revenue up 5.8% to $3.73B, adjusted EPS $4.99 beats; raises FY guidance
Q2 diluted EPS $3.64 vs $2.84 (+28.5%); adjusted EPS $4.99 vs $4.35 (+14.9%), beating prior guidance.
Labcorp declares $0.72 quarterly dividend payable Sept 11, 2026
Cash dividend of $0.72 per share declared by Board of Directors.
Labcorp to release Q2 2026 earnings on July 30, 2026
Earnings release before market open on Thursday, July 30, 2026.
Labcorp to present at Jefferies Global Healthcare Conference on June 3, 2026
Presentation scheduled for June 3, 2026, 12:15-12:45 pm ET in New York.
Labcorp shareholders elect 11 directors, approve say-on-pay, ratify Deloitte at 2026 annual meeting
All 11 director nominees elected: Garheng Kong received 50.1M for, 20.1M against (29% opposed); others received >90% support.
Labcorp Q1 revenue $3.54B (+5.8%), adjusted EPS $4.25 (+10.6%); raises FY guidance
Q1 diluted EPS $3.35 (+32.8% YoY); adjusted EPS $4.25 vs $3.84 consensus.
Labcorp declares $0.72 quarterly dividend; payable June 11, 2026
Dividend of $0.72 per share declared by Board of Directors.
Labcorp to announce Q1 2026 earnings on April 30, 2026 before market open
Earnings release scheduled for April 30, 2026 before market open, conference call at 9:00 a.m. ET.
Labcorp enters $750M senior unsecured term loan due 2028
$750M term loan fully funded on March 20, 2026; matures March 20, 2028.
Labcorp Q4 revenue $3.52B (+5.6% YoY), adj EPS $4.07 beat; guides FY26 adj EPS $17.55-18.25
Q4 revenue $3.52B (up 5.6% YoY, organic 3.8%); diluted EPS $1.98; adjusted EPS $4.07 vs $3.45.
Labcorp appoints John H. Sampson, M.D., Ph.D., to board of directors
Appointed John H. Sampson, M.D., Ph.D., to Board of Directors, effective February 9, 2026.
Labcorp extends receivables purchase agreement to Jan 2029, adds $125M accordion facility
Termination date extended to January 26, 2029.
Labcorp to release Q4 2025 earnings on Feb 17, 2026
Earnings release before market open on Tuesday, February 17, 2026.
Labcorp declares quarterly cash dividend of $0.72 per share
Dividend of $0.72 per share declared by Board of Directors.
Labcorp to Participate in Fireside Chat at 44th Annual J.P. Morgan Healthcare Conference
Labcorp (NYSE: LH) will speak in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 4:30 p.m. PT.
Labcorp EVP, President of Diagnostics Labs & COO Mark Schroeder to retire April 1, 2026
Mark Schroeder notified Labcorp of retirement effective April 1, 2026.
Labcorp announces retirement of board member Dr. D. Gary Gilliland
Dr. Gilliland will retire from the Labcorp board effective December 31, 2025.
Labcorp appoints Novartis U.S. President Victor Bulto to Board of Directors
Victor Bulto appointed to Labcorp's Board effective December 1, 2025; he is President of Novartis U.S. and member of Novartis Executive Committee.
Labcorp Q3 adjusted EPS $4.18 vs $3.50; raises FY adjusted EPS midpoint to $16.15-$16.50
Revenue $3.56B (+8.6% YoY); diluted EPS $3.12 (vs $2.00); adjusted EPS $4.18 (vs $3.50).
Labcorp declares quarterly cash dividend of $0.72 per share
Dividend of $0.72 per share declared by Labcorp's Board of Directors.
Labcorp schedules Q3 2025 earnings release for October 28 before market open
Earnings results will be released before market open on Tuesday, October 28, 2025.
Labcorp management to present at Morgan Stanley Healthcare Conference on Sept 9
Executive management team to speak at Morgan Stanley 23rd Annual Global Healthcare Conference.
Labcorp Q2 revenue $3.53B, Adj EPS $4.35; raises full-year guidance
Q2 revenue $3.53B (+9.5% YoY); diluted EPS $2.84 vs $2.43; adjusted EPS $4.35 vs $3.94.
Labcorp declares $0.72/share quarterly dividend payable Sept 11, 2025
Dividend of $0.72 per share of common stock declared by Board of Directors.
Labcorp enters $1B revolving credit facility maturing 2030, extending prior facility
New $1B senior unsecured revolver replaces prior facility maturing April 2026; now matures June 27, 2030.
Labcorp to announce Q2 2025 earnings on July 24, 2025; no results yet
Earnings release scheduled for before market open on July 24, 2025.
Labcorp shareholders re-elect all 10 directors, approve 2025 equity plans
All 10 directors elected with high majority; e.g., CEO Schechter received 64.4M for, 5.6M against.
Labcorp schedules annual shareholder meeting webcast for May 15, 2025
Annual meeting will be webcast live on May 15, 2025 at 9:00 a.m. ET.
Revenue $3.35B, GAAP diluted EPS $2.52 (down from $2.69), adjusted EPS $3.84 (up from $3.68).
Labcorp declares $0.72 per share quarterly dividend payable June 11
Quarterly cash dividend of $0.72 per share on common stock.
Labcorp to report Q1 2025 earnings on April 29 before market open
Earnings release before market open Tuesday, April 29, 2025; conference call at 9 a.m. ET.
Labcorp Q4 revenue $3.33B (+9.8% YoY); adj. EPS $3.45; FY2025 rev. midpoint ~$14.0B, adj. EPS $16.00
Q4 revenue $3.33B (+9.8% YoY); diluted EPS $1.70 vs ($1.95); adjusted EPS $3.45 vs $3.30; free cash flow $665.1M vs $412.4M.
Labcorp upsizes receivables facility from $300M to $700M, adds TD Bank and MUFG as purchasers
Facility limit increased from $300M to $700M under amended Receivables Purchase Agreement.
Labcorp declares $0.72 quarterly dividend, payable March 12, 2025
Cash dividend of $0.72 per common share declared by Board.
Labcorp to present at J.P. Morgan Healthcare Conference on Jan 14 at 3:45 p.m. PT
Labcorp executive management team will participate in a fireside chat on Jan 14, 2025 at 3:45 p.m. PT.
Labcorp to report Q4 2024 earnings on February 6, 2025
Earnings release before market open on Thursday, February 6, 2025.
Labcorp names Julia Wang CFO effective Dec 2; Glenn Eisenberg to retire April 2025
Julia Wang, former CFO of BeiGene, appointed EVP and CFO of Labcorp effective Dec 2, 2024.
Labcorp Q3 revenue $3.28B, adj EPS $3.50 vs $3.38; lowers FY adj EPS midpoint $0.10
Revenue $3.28B (+7.4% YoY); diluted EPS from cont ops $2.00 vs $2.11; adj EPS $3.50 vs $3.38.
Labcorp declares quarterly cash dividend of $0.72 per share
Dividend of $0.72 per share on common stock, payable December 13, 2024.
Labcorp schedules Q3 2024 earnings release for October 24, 2024
Q3 2024 results will be released before market open on Thursday, October 24, 2024.
Labcorp issues $2B in three tranches to refinance near-term debt maturities
Issued $650M 4.350% notes due 2030, $500M 4.550% notes due 2032, $850M 4.800% notes due 2034.
Labcorp subsidiary prices $2B senior notes offering to refinance existing debt
Labcorp subsidiary (LCAH) prices $2B in three senior note tranches: $650M at 4.350% due 2030, $500M at 4.550% due 2032, $850M at 4.800% due 2034.
Labcorp management to speak at Baird Healthcare Conference on Sept 10
Labcorp (LH) executive management will present at Baird 2024 Global Healthcare Conference.
Labcorp enters $300M accounts receivable securitization; accordion to $700M
Three-year $300M securitization facility with PNC Bank, dated August 23, 2024.
Labcorp Q2 revenue $3.22B (+6.2%), adj EPS $3.94; raises revenue guidance, boosts buyback $1B
Q2 revenue $3.22B (+6.2% YoY); diluted EPS $2.43 vs $1.74; adjusted EPS $3.94 vs $3.42.
Labcorp declares $0.72 quarterly dividend payable Sept 13, 2024
Quarterly cash dividend of $0.72 per share declared.
Labcorp announces Q2 2024 earnings release and conference call date
Results to be released before market open on August 1, 2024.
On November 19, 2024, Labcorp Holdings Inc. (“Labcorp”) announced that on November 15, 2024, Glenn Eisenberg notified Labcorp of his intention to retire from Labcorp effective April 30, 2025.
Julia Wang, age 54, was appointed to the position of Executive Vice President and Chief Financial Officer ("CFO").
As previously disclosed, on January 4, 2023, Paul Kirchgraber, Senior Advisor to the CEO, and former EVP and CEO of Labcorp’s Drug Development business segment, informed Laboratory Corporation of America Holdings (“Labcorp”) that he intended to depart Labcorp upon the completion of the spin-off of Fortrea Holdings Inc. in order to pursue other opportunities.
Laboratory Corporation of America Holdings (“Labcorp”) today announced that on June 5, 2023, Labcorp’s Board of Directors (the “Board”) appointed Paul B. Rothman as a member of the Board, effective June 6, 2023.
on May 4, 2023, Labcorp announced that Mark S. Schroeder, the current Executive Vice President, and President, Diagnostics Laboratory Operations and Global Supply Chain of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Diagnostics & Chief Operations Officer, effective May 1, 2023.
on May 4, 2023, Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Early Development & Chief Medical and Scientific Officer, effective May 1, 2023.
Mark S. Schroeder, the current Executive Vice President, and President, Diagnostics Laboratory Operations and Global Supply Chain of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Diagnostics & Chief Operations Officer, effective May 1, 2023.
Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Early Development & Chief Medical and Scientific Officer, effective May 1, 2023.
Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit effective January 9, 2023
Paul Kirchgraber, EVP and CEO of Labcorp’s Drug Development business segment informed Labcorp that he intends to depart Labcorp upon the completion of the planned spin-off in order to pursue other opportunities.
Laboratory Corporation of America Holdings (“Labcorp”) today announced that on October 12, 2022, Labcorp’s Board of Directors (the “Board”) appointed Kirsten M. Kliphouse as a member of the Board, effective immediately.
Max materiality 0.90 · Median 0.30 · Most common event other